Pages that link to "Q92892082"
Jump to navigation
Jump to search
The following pages link to Clifford A Hudis (Q92892082):
Displaying 50 items.
- Latent bone metastasis in breast cancer tied to Src-dependent survival signals (Q24648828) (← links)
- Breast cancer. Clinical practice guidelines in oncology (Q28308245) (← links)
- Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40 (Q33416887) (← links)
- American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer (Q33631047) (← links)
- Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial (Q33724456) (← links)
- PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). (Q33883406) (← links)
- Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104 (Q33897610) (← links)
- Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503) (Q33900866) (← links)
- Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). (Q33927979) (← links)
- Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901. (Q33927985) (← links)
- Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physicians (Q33990818) (← links)
- Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer on a clinical trial: CALGB 49907 and CALGB 361004 (alliance) (Q34168190) (← links)
- Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update (Q34421634) (← links)
- MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer (Q34557129) (← links)
- Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer (Q34601123) (← links)
- Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal (Q34611634) (← links)
- Invasive breast cancer (Q34619885) (← links)
- Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907. (Q34743448) (← links)
- Adjuvant chemotherapy in older women with early-stage breast cancer (Q34858284) (← links)
- Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer (Q35038093) (← links)
- p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905). (Q35146274) (← links)
- Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer (Q35569694) (← links)
- Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NC (Q35847455) (← links)
- Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer (Q36059237) (← links)
- A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. (Q36243420) (← links)
- Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance). (Q36294970) (← links)
- Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. (Q36389193) (← links)
- NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. (Q36409307) (← links)
- Cancer and leukemia group B breast committee: decades of progress and plans for the future (Q36494888) (← links)
- HER2 testing in breast cancer: NCCN Task Force report and recommendations. (Q36524447) (← links)
- Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy (Q36545157) (← links)
- Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B. (Q36794927) (← links)
- Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction (Q36875361) (← links)
- Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343 (Q36951718) (← links)
- Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide follow (Q37118467) (← links)
- Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013 (Q37163481) (← links)
- Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. (Q37166436) (← links)
- Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance) (Q37234829) (← links)
- A planned, prospective comparison of short-term quality of life outcomes among older patients with breast cancer treated with standard chemotherapy in a randomized clinical trial vs. an observational study: CALGB #49907 and #369901. (Q37542432) (← links)
- Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907. (Q37576583) (← links)
- Lymphedema, musculoskeletal events and arm function in older patients receiving adjuvant chemotherapy for breast cancer (Alliance A171302). (Q38616416) (← links)
- Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression (Q38736718) (← links)
- Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance). (Q38863741) (← links)
- Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative). (Q39019484) (← links)
- Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527 (Q39089103) (← links)
- Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer (Q44048395) (← links)
- Can we really use retrospective subset analyses and surveillance, epidemiology, and end results data to drive clinical practice? (Q44665153) (← links)
- Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer (Q45041166) (← links)
- Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. (Q49273085) (← links)
- Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? (Q54509553) (← links)